Startseite Kongressberichte 2017 Highlights Gastrointestinaltumoren Colon Cancer Role of Cetuximab

Prof. Heinz-Josef Lenz, USA

Statement on treatment of mCRC RASwt patients in first line and rating of the value of Cetuximab vs. Panitumumab and Bevacizumab?


 

Heinz-Josef Lenz - mCRC RASwt-first line Therapy from Oncoletter on Vimeo.

Prof. Dirk Arnold, Lissabon

Statement on treatment of mCRC RAS wildtype patients in first line and the mportance of EGFR-AB for patients with a RASwt mCRC in particular regarding Cetuximab and its value in this context:


 

Dirk Arnold - mCRC RASwt-first line Therapy from Oncoletter on Vimeo.

Prof. Sebastian Stintzing, München

Statement on treatment of mCRC RAS wildtype patients in first line and the mportance of EGFR-AB for patients with a RASwt mCRC in particular regarding Cetuximab and its value in this context:

 


 

Sebastian Stintzing - EGFR-AB for RASwt mCRC from Oncoletter on Vimeo.

Dr. med. Dominik Paul Modest, München

Right-sided colorectal cancer (RC): Response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR)

Dominik Modest explains the results and rates the importance of EGFR-AB for patients with a right sided mCRC RAS wt in particular regarding Cetuximab ad its value in this context:


 

Dominik Modest - EGFR-AB for right sided mCRC RAS wt from Oncoletter on Vimeo.